Phibro Animal Health (NASDAQ:PAHC) Upgraded at Zacks Research

Key Points

• Phibro Animal Health has been upgraded from a "hold" to a "strong-buy" rating by Zacks Research, with Q3 2026 earnings estimates set at $0.69 EPS.
• The company's stock is currently trading at $40.46, marking a significant gain of 3.3% on the trading day.
• Insider trading activity was noted, as CEO Jack Bendheim sold over 7,000 shares, resulting in an 18.31% decrease in his ownership of the stock.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was upgraded by research analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a report issued on Monday,Zacks.com reports. Zacks Research also issued estimates for Phibro Animal Health's Q3 2026 earnings at $0.69 EPS, Q1 2027 earnings at $0.65 EPS, Q3 2027 earnings at $0.63 EPS and FY2027 earnings at $2.55 EPS.

Other equities analysts also recently issued research reports about the company. BNP Paribas upgraded Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. JPMorgan Chase & Co. upgraded Phibro Animal Health from a "neutral" rating to an "overweight" rating and increased their price target for the company from $25.00 to $35.00 in a report on Monday, July 7th. Bank of America increased their price target on Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a report on Friday, August 29th. Morgan Stanley set a $34.00 price target on Phibro Animal Health in a report on Thursday, August 28th. Finally, BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target on the stock in a report on Monday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $28.40.

Phibro Animal Health Trading Up 3.3%

NASDAQ:PAHC opened at $40.46 on Monday. The stock's 50 day moving average price is $34.09 and its 200 day moving average price is $26.89. Phibro Animal Health has a 52 week low of $16.16 and a 52 week high of $41.57. The company has a market capitalization of $1.64 billion, a P/E ratio of 34.29, a P/E/G ratio of 1.18 and a beta of 0.89. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings data on Wednesday, August 27th. The company reported $0.57 EPS for the quarter, topping analysts' consensus estimates of $0.52 by $0.05. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The firm had revenue of $378.70 million for the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, research analysts forecast that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 7,022 shares of the stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $40.26, for a total value of $282,705.72. Following the completion of the sale, the chief executive officer directly owned 31,338 shares of the company's stock, valued at approximately $1,261,667.88. This represents a 18.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 24,622 shares of company stock valued at $995,893 over the last three months. 50.13% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. National Bank of Canada FI bought a new position in Phibro Animal Health in the first quarter worth $30,000. Financial Management Professionals Inc. bought a new position in Phibro Animal Health in the second quarter worth $32,000. EverSource Wealth Advisors LLC lifted its position in Phibro Animal Health by 7,671.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company's stock worth $69,000 after purchasing an additional 2,685 shares during the period. Tower Research Capital LLC TRC lifted its position in Phibro Animal Health by 768.2% in the second quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company's stock worth $118,000 after purchasing an additional 4,079 shares during the period. Finally, Curat Global LLC bought a new position in Phibro Animal Health in the first quarter worth $146,000. 99.34% of the stock is owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.